Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-small Cell Lung Cancer

Roche announced that it was made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® versus Tecentriq alone as an initial treatment for people with PD-L1-high locally advanced or metastatic NSCLC.